FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Torres Denice  (Last) (First) (Middle)					3. E	2. Issuer Name and Ticker or Trading Symbol     2seventy bio, Inc. [ TSVT ]  3. Date of Earliest Transaction (Month/Day/Year)									ck all applic Directo Officer	tionship of Reportin all applicable) Director Officer (give title below)		son(s) to Iss 10% Ov Other (s below)	wner
2SEVENTY BIO, INC. 60 BINNEY STREET						/08/2 f Ame		Date o	f Original	Filed	(Month/Da	ay/Year)			ividual or J	oint/Group	Filing	(Check Ap	plicable
(Street)	IDGE M	IA	02142											Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
(City)	(5	state)	(Zip)																
		Tab	le I - Non	-Deriv	ative	e Se	curities	s Acc	quired,	Dis	posed o	f, or Be	nefic	ially	Owned				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution Date,		Date,	e, Transaction Disposed Code (Instr. 5)		ties Acquired (A) or d Of (D) (Instr. 3, 4 a		or and	5. Amour Securitie Beneficia Owned F Reported	es Form ally (D) of Following (I) (II		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) o (D)	(A) or (D) Pri		Transact	Transaction(s) (Instr. 3 and 4)			(111541. 4)
Common Stock <sup>(1)</sup> 06/08/					3/2022		Α		8,200	8,200 A S		0.00	11,110			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date Exec (Month/Day/Year) if an	3A. Deemed Execution D if any (Month/Day/	ution Date, T		ction Instr.	of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)		Date Exercisab		Expiration Date	Title	Amo or Num of Shar	ber					
Stock Option (right to buy)	\$13.51	06/08/2022			A		16,900		(2)	0	06/08/2032	Common Stock	16,9	000	\$0.00	16,90	0	D	

## **Explanation of Responses:**

- 1. These restricted stock units yest 100% on the earlier of June 8, 2023 or the date of the next annual meeting of stockholder of 2seventy bio, Inc.
- 2. This option vests 100% on the earlier of June 8, 2023 or the date of the next annual meeting of stockholders of 2seventy bio, Inc.

## Remarks:

/s/ Teresa Jurgensen, Attorneyin-Fact

06/09/2022

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.